Is Cyltezo (adalimumab) safe for elderly patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cyltezo Safety in Elderly Patients

Cyltezo (adalimumab-adbm) can be used in elderly patients, but requires heightened vigilance due to significantly increased risks of serious infections and malignancies compared to younger adults. The FDA label explicitly states that among patients ≥65 years, the frequency of serious infection and malignancy was higher than in those <65 years 1.

Key Safety Considerations

Infection Risk - The Primary Concern

Elderly patients face substantially elevated infection risk, with up to a 20-fold increase in severe infections when treated with adalimumab products 2. The most critical factors include:

  • Age thresholds: Risk increases at ages 45,50, and particularly ≥65 years, with patients >65 years showing severe infection rates of 11% versus 0.5% in younger patients 2
  • Combination therapy dramatically amplifies risk: Odds ratio increases from 2.9 for monotherapy to 14.5 for combination with thiopurines and/or steroids 2
  • Specific infection patterns: Fungal and mycobacterial infections are particularly associated with anti-TNF agents like adalimumab 2

Malignancy Risk

The FDA label mandates close monitoring for malignancy development in elderly patients 1. Current evidence shows:

  • Increased risk of non-melanoma skin cancers and lymphoma, particularly with thiopurine combination therapy 3
  • Skin cancer risk: NMSC hazard ratio 1.7 (95% CI 1.3-2.2) and melanoma 2.6 (95% CI 1.0-6.7) with infliximab (similar class) 4

Clinical Decision Framework

When to Use Cyltezo in Elderly Patients

Consider adalimumab when:

  • Disease severity warrants biologic therapy despite age-related risks
  • Patient has no active infections or recent serious infections
  • Tuberculosis screening is negative (or latent TB adequately treated)
  • Comorbidities are optimized
  • Patient can be monitored closely for infection signs

When to Choose Alternative Therapies

Prioritize gut-selective biologics (vedolizumab) or IL-12/23 inhibitors (ustekinumab) in elderly patients when clinically appropriate, as these show lower systemic infection risk 5, 2, 3. The 2021 ECCO guidelines specifically note vedolizumab's trend toward lower non-gastrointestinal infections 2.

For elderly patients >60 years in sustained remission on thiopurines, consider stopping after discussion with the IBD team 5, which would eliminate the need for high-risk combination therapy if adalimumab is being considered.

Mandatory Monitoring Protocol

Pre-Treatment Assessment

  • Tuberculin skin test and chest X-ray (consider ≥5mm induration positive even with prior BCG) 6, 1
  • Hepatitis B serology 6
  • Assessment for endemic fungal exposure (histoplasmosis, coccidioidomycosis, blastomycosis) 6, 1
  • Comprehensive comorbidity evaluation 3

During Treatment

  • Temperature monitoring: Instruct patients to check frequently and report fever immediately 6
  • Monthly clinical assessment for infection signs: cough, fever, chills, wound infections, urinary symptoms, respiratory changes 6
  • Close monitoring for new infections, particularly in first year when hazard is highest 7
  • Vigilance for atypical presentations of tuberculosis and opportunistic infections 1

Common Pitfalls to Avoid

  1. Underestimating combination therapy risk: The combination of adalimumab with corticosteroids and/or thiopurines creates multiplicative rather than additive infection risk in elderly patients 2

  2. Inadequate TB screening: False-negative tuberculin tests can occur; maintain high clinical suspicion even with negative screening 1

  3. Ignoring functional status: Chronologic age alone is insufficient—assess frailty, comorbidities, and functional status 3

  4. Delayed infection recognition: Elderly patients may present with atypical infection symptoms; maintain low threshold for evaluation 1

Efficacy Considerations

Efficacy appears preserved in elderly patients 1. Recent 2025 data in rheumatoid arthritis showed sustained 24-month efficacy in patients ≥60 years, though those with high baseline inflammatory burden (DAS28-CRP ≥5.1, ESR ≥40 mm/h) had poorer outcomes 8. A 2021 uveitis study demonstrated significant improvements in elderly patients ≥60 years with acceptable adverse event rates of 26.8% 9.

Bottom Line

The decision to use Cyltezo in elderly patients requires explicit risk-benefit discussion prioritizing infection and malignancy surveillance over convenience. When disease severity justifies biologic therapy, adalimumab can be effective, but alternative biologics with more favorable safety profiles in the elderly (vedolizumab, ustekinumab) should be strongly considered first 5, 2, 3. If adalimumab is chosen, avoid combination immunosuppression when possible, ensure rigorous pre-treatment screening, and maintain intensive monitoring throughout treatment.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.